Arterial intima-media thickness in 13-year-old adolescents and previous antichlamydial antimicrobial use: A retrospective follow-up study

Pediatrics

Volumn 122, Issue 3, 2008, Pages

  Volanen, Lina ^a,b   Kallio, Katariina ^a,c   Saarinen, Maiju ^a   Järvisalo, Ikkoj ^a,d   Vainionpää, Raija ^e   Rönnemaa, Tapani ^d   Viikari, Jorma ^d   Marniemi, Jukka ^f   Simell, Olli ^c   Raitakari, Olli T ^a,g  

^a UNIVERSITY OF TURKU   (Finland)

^b Drug Development and Therapeutics   (Finland)

^c Departments of Pediatrics and Adolescent Medicine   (Finland)

^d Departments of Medicine   (Finland)

^e Departments of Virology   (Finland)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g UNIVERSITY OF TURKU   (Finland)

Author keywords

Antimicrobial agents; Atherosclerosis; Infection; Prevention; Ultrasound

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; C REACTIVE PROTEIN; CEFADROXIL; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; COTRIMAZINE; DOXYCYCLINE; MACROLIDE; PENICILLIN DERIVATIVE; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY;

ABDOMINAL AORTA; ADOLESCENT; AORTA; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CHILD; CHLAMYDIAL PNEUMONIA; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; ECHOGRAPHY; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMON CAROTID ARTERY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; IMMUNOLOGY; INFANT; INTIMA; ISOLATION AND PURIFICATION; MICROBIOLOGY; PRESCHOOL CHILD; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; AORTA, ABDOMINAL; ATHEROSCLEROSIS; CAROTID ARTERY, COMMON; CHILD; CHILD, PRESCHOOL; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUNICA INTIMA;

EID: 51649093846     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0220     Document Type: Article

References (32)

1. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2(8618):983-986
2. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96(2):404-407
3. Maass M, Barters C, Engel PM, Mamat U, Sievers H-H. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31(4):827-832
4. Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipopro- tein E-knockout mice. Circulation. 2000;102(9):1039-1044
5. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity. Circulation. 2001;103(10):1390-1395
6. Volanen I, Jarvisalo MJ, Vainionpaa R, et al. Increased aortic intima-media thickness in 11-year-old healthy children with persistent Chlamydia pneumoniae seropositivity. Arterioscler Thromb Vasc Biol. 2006;26(3):649-655
7. Monster TB, Johnsen SP, Olsen ML, et al. Antibiotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Ther. 2005;12(3): 226-232
8. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA. 2005;293(21): 2641-2647
9. Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomised placebo controlled multicentre trial to assess short term clar- ithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ. 2006;332(7532):22-27
10. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 2002;105(11):1298- 1303
11. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97(7):633-636
12. Liuba P, Persson J, Luoma J, Ylä-Herttuala S, Pesonen E. Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media. Eur Heart J. 2003;24(6): 515-521
13. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation. 2002;106(19):2428-2433
14. Melissano G, Blasi F, Esposito G, et al. Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study. Eur J Vasc Endovasc Surg. 1999;18(4): 355-359
15. McGill HC Jr, McMahan CA, Herderick EE, et al. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 2000;20(3): 836-845
16. Niinikoski H, Viikari J, Ronnemaa T, et al. Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life. The STRIP baby project. Circulation. 1996; 94(6):1386-1393
17. Klaukka T. The Finnish database on drug utilisation. Nor J Epidemiol. 2001;11(1):19-22
18. Järvisalo MJ, Jartti L, Nanto-Salonen K, et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation. 2001;104(24): 2943-2947
19. World Health Organization, Collaborating Centre for Drug Statistics Methodology. The ATC/DDD system. Available at: www. whocc.no/atcddd. Accessed October 6, 2006
20. Freidank HM, Losch P, Vögele H, Wiedmann-Al-Ahmad M. In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations. Antimicrob Agents Chemother. 1999;43(7):1808-1810
21. Rask-Nissilä L, Jokinen E, Terho P, et al. Neurological development of 5-year-old children receiving a low-saturated fat, low-cholesterol diet since infancy: a randomized controlledtrial. JAMA. 2000;284(8):993-1000
22. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;116(9):1032-1040
23. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. NEnglJMed. 1999;340(1):14-22
24. Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke. 2006;37(1): 87-92
25. Kutlin A, Roblin PM, Hammerschlag MR. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother. 1999; 43(9):2268-2272
26. Gieffers J, Fullgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001;103(3):351-356
27. Gieffers J, van Zandbergen G, Rupp J, et al. Phagocytes transmit Chlamydia pneumoniae from the lungs to the vasculature. Eur Respir J. 2004;23(4):506-510
28. Gieffers J, Rupp J, Gebert A, Solbach W, Klinger M. First- choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae. Antimicrob Agents Chemother. 2004;48(4):1402-1405
29. Huittinen T, Leinonen M, Tenkanen L, et al. Synergistic effect of persistent Chlamydia pneumoniae infection, autoimmunity, and inflammation on coronary risk. Circulation. 2003;107(20): 2566 -2570
30. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352(16):1646-1654
31. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637-1645
32. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity. Circulation. 2004;109(8):1010-1015 33. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA. 1999;281(5):427-431